M1095-PSA-301: A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs

sonelokimab (M1095) - Avillion, MoonLake Immunotherap

Apr 6, 2026